| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2006 | CA2189567C Substituted fused and bridged bicyclic compounds as therapeutic agents |
| 02/14/2006 | CA2180155C Naphthylamides as central nervous system agents |
| 02/14/2006 | CA2178605C Pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors |
| 02/14/2006 | CA2163197C Tri(platinum) complexes |
| 02/14/2006 | CA2135926C Substituted hexahydrobenzo[a]phenanthridines |
| 02/14/2006 | CA2130618C Stereoselective process for preparing .beta.-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonate intermediates |
| 02/14/2006 | CA2105666C New centrally acting substituted phenylazacycloalkanes |
| 02/12/2006 | CA2476101A1 Extended-release capsules comprising venlafaxine hydrochloride |
| 02/11/2006 | CA2515754A1 Kit for dip coating medical devices comprising an aqueous latex polymeric emulsion |
| 02/09/2006 | WO2006015338A2 Crystalline form of donepezil hydrochloride |
| 02/09/2006 | WO2006015283A2 Treatment of benign prostatic hyperplasia |
| 02/09/2006 | WO2006015263A2 Lonidamine analogs |
| 02/09/2006 | WO2006015261A2 Nucleoside phosphonate conjugates as anti hiv agents |
| 02/09/2006 | WO2006015259A2 Compounds and compositions as modulators of steroid hormone nuclear receptors |
| 02/09/2006 | WO2006015232A2 Use of methyl pyruvate for the purpose of increasing muscle energy production |
| 02/09/2006 | WO2006015171A2 Use of glycosoaminoglycans for the prevention and treatment of sepsis |
| 02/09/2006 | WO2006015159A2 Potassium channel inhibitors |
| 02/09/2006 | WO2006015154A2 Compositions and methods for nutrition supplementation |
| 02/09/2006 | WO2006015124A2 Fused ring heterocycle kinase modulators |
| 02/09/2006 | WO2006015120A2 Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| 02/09/2006 | WO2006015093A1 Hydrophobic, hydrophilic wound composition for delivery of pharmaceutical (s) to wet surfaces or in aqueous environments |
| 02/09/2006 | WO2006014968A2 Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| 02/09/2006 | WO2006014918A2 Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| 02/09/2006 | WO2006014916A2 Preparation of trandolapril |
| 02/09/2006 | WO2006014913A2 Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase |
| 02/09/2006 | WO2006014911A2 Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin |
| 02/09/2006 | WO2006014903A2 Compositions and methods of use for adam12 antagonists in treating disease |
| 02/09/2006 | WO2006014877A2 Potassium channel inhibitors |
| 02/09/2006 | WO2006014865A2 Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
| 02/09/2006 | WO2006014864A2 Methods and compositions for reducing c-reactive protein |
| 02/09/2006 | WO2006014828A1 Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides |
| 02/09/2006 | WO2006014790A2 Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses |
| 02/09/2006 | WO2006014787A2 Compositions containing policosanol and b vitamins and their pharmaceutical uses |
| 02/09/2006 | WO2006014780A2 Methods and compositions for treating or preventing macular-degeneration related disorders |
| 02/09/2006 | WO2006014762A1 Substituted amide beta secretase inhibitors |
| 02/09/2006 | WO2006014703A2 Homopiperdinine derivatives as nk-1 antagonists |
| 02/09/2006 | WO2006014669A2 Methods and compositions for treatment of intraepithelial neoplasia |
| 02/09/2006 | WO2006014665A2 Arylpyrrolidine derivatives as nk-1/ssri antagonists |
| 02/09/2006 | WO2006014664A2 Cyclopentylamine and cyclohexylamine derivatives as nk-1/ssri antagonists |
| 02/09/2006 | WO2006014653A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | WO2006014647A2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| 02/09/2006 | WO2006014618A2 Substituted pyrazoles, compositions containing such compounds and methods of use |
| 02/09/2006 | WO2006014579A2 Enhancing class i antigen presentation with synthetic sequences |
| 02/09/2006 | WO2006014534A2 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | WO2006014526A2 Compositions and methods relating to novel compounds and targets thereof |
| 02/09/2006 | WO2006014507A2 Method for inhibiting lipid peroxidation |
| 02/09/2006 | WO2006014468A2 Saif, an anti-inflammatory factor, and methods of use thereof |
| 02/09/2006 | WO2006014394A1 Modified pyrimidine glucocorticoid receptor modulators |
| 02/09/2006 | WO2006014353A2 Glycogen or polysaccharide storage disease treatment method |
| 02/09/2006 | WO2006014325A2 C-met modulators and method of use |
| 02/09/2006 | WO2006014290A2 Anti-inflammatory medicaments |
| 02/09/2006 | WO2006014262A2 Indoles having anti-diabetic activity |
| 02/09/2006 | WO2006014244A2 Stable cleanser compositions containing sulfur |
| 02/09/2006 | WO2006014237A2 Triple anti-irritant composition |
| 02/09/2006 | WO2006014236A1 Delivery system for topical medications |
| 02/09/2006 | WO2006014219A2 Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral la-plus salts |
| 02/09/2006 | WO2006014194A1 Oligosaccharide-containing compositions and uses thereof |
| 02/09/2006 | WO2006014185A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/09/2006 | WO2006014168A1 Nicotinamide derivatives and their use as therapeutic agents |
| 02/09/2006 | WO2006014024A1 Therapeutic agent for psychoneurotic disease |
| 02/09/2006 | WO2006014005A1 Pyrazole derivative |
| 02/09/2006 | WO2006013963A1 External preparation for nail |
| 02/09/2006 | WO2006013960A1 Salts of benzimidazole derivative with amines and process for production thereof |
| 02/09/2006 | WO2006013954A1 Composition containing swelling agent comprising swellable water-soluble polysaccharide and food, obesity preventive, and constipation alleviator each containing the composition |
| 02/09/2006 | WO2006013948A1 Triazole derivative |
| 02/09/2006 | WO2006013929A1 Composition for accelerating calcium absorption |
| 02/09/2006 | WO2006013914A1 Preparation for administration to mouth mucosa |
| 02/09/2006 | WO2006013904A1 Medicinal composition containing meltrin antagonist |
| 02/09/2006 | WO2006013873A1 Drugs having cyclooxygenase inhibiting activity |
| 02/09/2006 | WO2006013545A1 Pharmaceutical compositions of irbesartan |
| 02/09/2006 | WO2006013444A1 Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
| 02/09/2006 | WO2006013409A1 Antibacterial agents |
| 02/09/2006 | WO2006013359A1 Medicaments for treating chronic respiratory disease |
| 02/09/2006 | WO2006013335A1 Stabilised prostaglandin composition |
| 02/09/2006 | WO2006013227A2 METHYLAMINE RISKS and TREATMENT WITH N-DERIVATIVES OF HYPERACTIVITY, DEPRESSION AND ALCOHOLISM |
| 02/09/2006 | WO2006013209A2 Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| 02/09/2006 | WO2006013203A2 Prodrugs activated by rna-dependent dna-polymerases |
| 02/09/2006 | WO2006013195A1 5-substituted 1h-pyrrolo[3,2-b]pyridines |
| 02/09/2006 | WO2006013073A1 Alkyl-and piperidine-substituted benzimidazole-derivates |
| 02/09/2006 | WO2006013049A2 Benzyloxy derivatives as maob inhibitors |
| 02/09/2006 | WO2006013048A1 Indole, indazole or indoline derivatives |
| 02/09/2006 | WO2006013003A1 Use of products derived from selenoprotein t, in its application related to calcium homeostasis |
| 02/09/2006 | WO2006012958A2 Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 02/09/2006 | WO2006012951A1 Use of organic glucosamine salts |
| 02/09/2006 | WO2006012896A1 Cellular transfer of nucleic acid materials |
| 02/09/2006 | WO2006000158A8 The use of laetispicine for manufacture of pharmaceutical composition |
| 02/09/2006 | WO2005123670A3 Crystalline form of a substituted pyrrolidine compound |
| 02/09/2006 | WO2005121065A3 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS |
| 02/09/2006 | WO2005120436A3 Composition for treating post-surgical pain |
| 02/09/2006 | WO2005118558A3 Pyrimidine compounds and use thereof |
| 02/09/2006 | WO2005118511A3 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 02/09/2006 | WO2005113004A3 Small molecule inhibitors for mrp1 and other multidrug transporters |
| 02/09/2006 | WO2005112913B1 Transthyretin stabilization |
| 02/09/2006 | WO2005111053A3 Pharmaceutical compositions having anti-inflammatory activity |
| 02/09/2006 | WO2005110085A3 Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| 02/09/2006 | WO2005108617A3 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| 02/09/2006 | WO2005108392A3 Process for preparing ondansetron hydrochloride dihydrate having a defined particle size |
| 02/09/2006 | WO2005105803A3 Purine derivatives as a1 adenosine receptor antagonists |
| 02/09/2006 | WO2005102334A3 Apparatus and method for transdermal delivery of fentany-based agents |
| 02/09/2006 | WO2005097089A3 Derivatives of leinamycin for use as anticancer agents |